Results 181 to 190 of about 10,598 (216)

Understanding the Promise and Challenges of Tumor-Agnostic Therapy: Could One Size Really Fit All? [PDF]

Cancers (Basel)
Myat YM, Thein KZ, Han MM, Ahluwalia M, Mukherjee S, Aung KL.   +5 more
europepmc   +1 more source

Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer [PDF]

Lung Cancer, 2021
Purpose: The small molecule inhibitors larotrectinib and entrectinib have recently been approved as cancer agnostic drugs in patients with tumours harbouring a rearrangement of the neurotrophic tropomyosin receptor kinase (NTRK).
Hans Brunnström, Patrick Micke, Hedvig Elfving   +2 more
exaly   +5 more sources

A review of NTRK fusions in cancer

Annals of Medicine and Surgery, 2022
The family of the neurotrophic tropomyosin kinase receptors (NTRK or TRK) is a part of the transmembrane tyrosine kinases responsible for neuronal development. The members of this receptor family are TRKA, TRKB and TRKC and they are encoded by the genes NTRK1, NTRK2 and NTRK3.
Dragos Serban, Dumitru Cristinel Badiu, Catalin Gabriel Smarandache   +2 more
exaly   +3 more sources

NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects

Diagnostics, 2021
: Tropomyosin receptor kinase (TK) is encoded by the neurotrophic tyrosine receptor kinase genes (NTRK) 1, 2, and 3, whose activation plays an important role in cell cycle proliferation and survival. Fusions of one of these genes can lead to constitutive
Vasiliki Siozopoulou, Evelien Smits, Koen De Winne   +2 more
exaly   +1 more source

Limited Accuracy of Pan-Trk Immunohistochemistry Screening for NTRK Rearrangements in Follicular-Derived Thyroid Carcinoma

International Journal of Molecular Sciences, 2022
Patients with advanced thyroid cancer harboring NTRK rearrangements can be treated with highly effective selective inhibitors. Immunohistochemistry (IHC) analysis, to detect Trk protein expression, represents an appealing screening strategy for NTRK ...
Alessio Basolo, Agnese Proietti, Anello Marcello Poma   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

NTRK point mutations and their functional consequences

Cancer Genetics, 2022
The neurotrophic receptor tyrosine kinase (NTRK) family of genes, including NTRK1, NTRK2, and NTRK3, encodes membrane-bound receptors that normally regulate cell survival and differentiation upon binding of growth factors. Not surprisingly, mutations in these genes are known to contribute to the growth of a diverse number of cancers.
Corey, Rogers, Jennifer J D, Morrissette, Robyn T, Sussman   +2 more
openaire   +2 more sources

NTRK Fusion Genes in Thyroid Carcinomas: Clinicopathological Characteristics and Their Impacts on Prognosis

Cancers, 2021
Chromosomal rearrangements of NTRK genes are oncogenic driver mutations in thyroid cancer (TC). This study aimed to identify NTRK fusion-positive thyroid tumors and to correlate them with clinical and pathological data and determine their prognostic ...
Bela Bendlova, Rami Katra, Martin Chovanec   +2 more
exaly   +2 more sources

NTRK-Fusions – A new kid on the block

Pathology - Research and Practice, 2019
The neurotrophic tyrosine receptor kinases (NTRK) play an important role in the development and function of the nervous system. Fusions involving NTRK and a wide range of genes that act as fusion partners are oncogenic and activate well-known signal transduction pathways like the MAPK-ERK pathway.
Märkl, Bruno, Hirschbühl, Klaus, Dhillon, Christine   +2 more
openaire   +2 more sources

[NTRK Gene Fusions and Treatment in NTRK Fusion-Positive Solid Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy, 2022
Neurotrophic tyrosine receptor kinase(NTRK)gene variants have been reported in a variety of cancer types. The prevalence of NTRK gene variants is less than 1% in many types of solid cancer. The highest NTRK gene fusions frequencies were found in secretary breast carcinoma and infantile fibrosarcoma.
Misao, Fukuda, Yoichi, Naito
openaire   +1 more source

NTRK‐rearranged mesenchymal tumour with epithelioid features: expanding the morphological spectrum of NTRK‐fused neoplasms

Histopathology, 2021
Neurotrophic tropomyosin receptor kinase (NTRK) fusion positive neoplasms were first identified in colorectal carcinoma almost 40 years ago1 . The availability of tyrosine kinase inhibitors specifically targeting receptors encoded by NTRK genes (Trk receptors), together with a considerable clinical response and favourable safety profile has sparked ...
João Victor Alves de Castro, Felipe D’Almeida Costa, Giovana Tardin Torrezan, Dirce Maria Carraro, Ulisses Ribaldo Nicolau, Antônio Geraldo do Nascimento   +5 more
openaire   +2 more sources